SAN MARINO, Calif., Dec. 16 Epeius BiotechnologiesCorporation, a leader in tumor-targeted gene delivery systems, has receivedtwo additional European patents for the platform targeting technologies andmolecular designs that enable precision gene delivery to primary cancers andmetastatic lesions that have spread throughout the body. With profounddemonstrations of clinical benefit and single-agent-efficacy, as well asoverall safety, Epeius Biotech continues to lead the field of clinical genemedicine with the advent of pathotropic (or disease-seeking) targeting. Theselatest EU patents follow on the heels of a major clinical patent that wasrecently awarded in the USA for targeted gene delivery in vivo. Togetherthese clinical patents provide additional intellectual property protection forthe platform of highly advanced biotechnologies embodied in the company'sleading anti-cancer agent Rexin-G(R) -- the first and so far onlytumor-targeted gene delivery system that has been successfully validated inthe clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a newgeneration of powerful biological anti-cancer agents that are exceedinglyprecise and highly selective for diseased tissues is currently in clinicaldevelopment. Anti-cancer agents such as Rexin-G(R) can be delivered by simpleintravenous infusion, yet are programmed to seek-out and accumulateselectively in primary and metastatic lesions that have spread throughout thebody, delivering a tumor-killing gene while sparing normal cells and tissues.Representing the world's first targeted genetic medicine proven to be bothsafe and effective in the clinic, Rexin-G(R) is commercially available in thePhilippines -- for use in all solid tumors that are refractory to standardchemotherapy -- and is currently in clinical trials in the USA for severaltypes of cancer.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceuticalcompany dedicated to the advancement of genetic medicine with the developmentand commercialization of its proprietary targeted delivery systems. To learnmore about our pipeline of proprietary biotechnologies currently available forclinical development and/or new product development, please visit us athttp://www.epeiusbiotech.com.
For more information about Rexin-G(R), on-going clinical trials in the USAand abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems,please contact Erlinda M. Gordon, M.D., at email@example.com.
*(LOGO 72dpi: Send2press.com/mediaboom/08-0421-Epeius_72dpi.jpg)
This release was issued on behalf of the above organization bySend2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Epeius Biotechnologies